Mary F. Mulcahy

Hematology | Oncology

675 N Saint Clair St Ste 100 Fl 21
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 113 publications

KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials.

KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials.

Journal: Cancers

Published: May 17, 2026

Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).

Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 17, 2026

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.

Journal: Nature medicine

Published: October 15, 2025

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201.

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201.

Journal: The oncologist

Published: May 15, 2025

Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: May 09, 2025

Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers.

Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers.

Journal: ESMO open

Published: March 31, 2025

Delta Radiomics and Tumor Size: A New Predictive Radiomics Model for Chemotherapy Response in Liver Metastases from Breast and Colorectal Cancer.

Delta Radiomics and Tumor Size: A New Predictive Radiomics Model for Chemotherapy Response in Liver Metastases from Breast and Colorectal Cancer.

Journal: Tomography (Ann Arbor, Mich.)

Published: December 23, 2024

Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma.

Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma.

Journal: The oncologist

Published: November 17, 2024

Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer.

Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer.

Journal: ESMO open

Published: August 23, 2024

NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.

NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: August 16, 2024

A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.

A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.

Journal: Cancer

Published: June 19, 2024

Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 11, 2024

Showing 1-12 of 113

Last Updated: 09/26/2026